South Korean (KOSPI) Healthcare Sector Analysis

Date	Market Cap	Revenue	Earnings	PE
Thu, 20 Jan 2022	₩231.4t	₩49.0t	₩4.3t	21.7x
Sat, 18 Dec 2021	₩272.8t	₩49.0t	₩4.3t	25.3x
Mon, 15 Nov 2021	₩256.1t	₩48.0t	₩4.3t	21.9x
Wed, 13 Oct 2021	₩258.7t	₩48.0t	₩4.3t	22.4x
Fri, 10 Sep 2021	₩304.3t	₩49.5t	₩4.3t	28x
Sun, 08 Aug 2021	₩306.1t	₩48.8t	₩4.2t	29.1x
Sat, 01 May 2021	₩273.2t	₩44.3t	₩2.9t	26.2x
Tue, 02 Feb 2021	₩274.9t	₩42.7t	₩2.2t	26.6x
Fri, 06 Nov 2020	₩230.5t	₩41.1t	₩1.6t	27.5x
Mon, 10 Aug 2020	₩242.6t	₩39.3t	₩1.0t	32.8x
Sun, 03 May 2020	₩165.6t	₩37.7t	₩855.3b	24.9x
Wed, 05 Feb 2020	₩140.4t	₩36.6t	₩803.2b	26.9x
Sat, 09 Nov 2019	₩140.2t	₩34.3t	₩856.9b	22.3x
Fri, 02 Aug 2019	₩125.9t	₩33.3t	₩925.4b	25.8x
Mon, 06 May 2019	₩162.8t	₩32.5t	₩923.2b	34.7x
Thu, 07 Feb 2019	₩164.4t	₩31.7t	₩956.7b	33.7x


Medical Equipment	-4.71%
Life Sciences	-6.12%
Pharma	-7.62%
Healthtech	-7.81%
Biotech	-12.30%
Healthcare Services	-17.72%

Company	Last Price	7D	1Y	Valuation
A298380 ABL Bio	₩32.10k	18.0% +₩230.9b	21.8%	PS150.9x
A142760 Bioleaders	₩12.05k	46.1% +₩108.9b	102.5%	PS3.5x
A137310 SD BioSensor	₩51.40k	1.0% +₩51.3b	n/a	PE4.2x
A294090 EOFLOWLtd	₩25.85k	6.5% +₩36.4b	-32.3%	PS1270.5x
A241820 PCL	₩41.00k	4.6% +₩18.7b	31.6%	PS9.9x

Jan 13

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

Novavax, Inc. and SK bioscience Co. Limited announced that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a Biologics License Application (BLA) from SK bioscience for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization in individuals 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2. Nuvaxovid™, Novavax' COVID-19 vaccine also known as NVX-CoV2373, is the first protein-based COVID-19 vaccine to be approved for commercial use in South Korea and will be manufactured and marketed in the country by SK bioscience. SK bioscience has an advance purchase agreement with the South Korean government to supply 40 million doses of Novavax' vaccine. The companies also recently announced expanded collaboration and license agreements that are expected to increase manufacturing capacity and provide SK bioscience with additional non-exclusive territories. Novavax' vaccine also recently received conditional marketing authorization (CMA) in the European Union and emergency use listing (EUL) from the World Health Organization (WHO) under the brand name Nuvaxovid. The Novavax/Serum Institute of India Pvt. Ltd. vaccine (brand name, Covovax™) recently received emergency use authorization (EUA) in India, Indonesia and the Philippines, as well as WHO EUL. Together, the WHO EULs for the vaccine from both companies reflect the potential opportunity for authorization in over 170 countries. The vaccine is also currently under review by multiple additional regulatory agencies worldwide and the company expects to receive additional worldwide authorizations in the first half of 2022. This includes the submission of its complete chemistry, manufacturing and controls (CMC) data package to the U.S. Food and Drug Administration (FDA) at the end of 2021. The company expects to submit a request for EUA for the vaccine in the U.S. after one month in accordance with guidance from the FDA regarding submission of all EUA vaccines.

Jun 15

Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis

Bridge Biotherapeutics (KQ288330) announced the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). The Phase IIa, is a two-phase study, with a randomized, double-blind, placebo-controlled induction phase, followed by a response-adaptive, double-blind extension phase. This multinational study will assess the safety and efficacy profiles of the investigational drug in 36 patients with moderate to severe ulcerative colitis, by activating 36 clinical trial sites across 5 countries (USA, Republic of Korea, New Zealand, Poland and Ukraine). The primary and secondary endpoints of the study consist of efficacy and safety assessments measured 8 weeks after drug administration. These include the clinical response and remission rates determined from the total Mayo score as well as the endoscopic remission rate, which is calculated based on the Mayo endoscopic subscore. Upon the completion of the low dose study, which was the first-in-patient study for BBT-401, the drug formulation has been enhanced in terms of its drug delivery and distribution to the ileum and distant colon. The enhanced drug delivery and distribution profile was evaluated via the in vitro Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model. BBT-401, an investigational drug with the potential to exhibit treatment efficacy in inflammatory diseases such as ulcerative colitis, is a GI-tract restricted small molecule Pellino-1 inhibitor. Pellino proteins serve as scaffold proteins that bind to proteins in inflammatory signaling pathways, including IRAK4, MyD88 and to RIPK1 in various physio-pathological conditions. In conjunction with the orally administered PoCP study, a proof of mechanism trial has been initiated in New Zealand, exploring the efficacy and safety of a rectal administration of BBT-401 in patients with active ulcerative colitis.

South Korean (KOSPI) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

A326030

Consensus EPS estimates have been upgraded.

A068270

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

A302440

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

A091990

Celltrion Group Announces Positive Results for Its Cocktail Therapy Candidates Including Neutralisation Data Against Omicron Variant

A196170

Forecast breakeven date pushed back to 2022

A008930

Upcoming dividend of ₩196 per share

A214370

Upcoming dividend of ₩1,300 per share

A207940

Third quarter 2021 earnings released: EPS ₩1,992 (vs ₩848 in 3Q 2020)

A137310

Investor sentiment deteriorated over the past week

A294090

EOFLOW Co.,Ltd. announced that it has received KRW 3.50004641 billion in funding from UXN Co., Ltd.

A298380

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

A241820

Investor sentiment deteriorated over the past week

A288330

Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis

A068760

Does Celltrion Pharm (KOSDAQ:068760) Deserve A Spot On Your Watchlist?

A142760

New 90-day low: ₩5,300

A046210

New 90-day high: ₩5,180